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authors then added bevacizumab to the 
same chemotherapy and the brain metas-
tases markedly shrank.
To date, it has been prospectively 
demonstrated that bevacizumab is safe 
and effective in NSCLC patients with 
brain metastases as long as these metas-
tases are pretreated2 or asymptomatic.3 
Moreover, a case series has shown that 
bevacizumab is also safe and effective for 
NSCLC patients with symptomatic, heav-
ily pretreated brain metastases.4 We also 
experienced a case of lung adenocarci-
noma in which the brain metastases were 
refractory to whole-brain irradiation but 
dramatically responded to combination 
chemotherapy of bevacizumab, pacli-
taxel, and carboplatin (Fig. 1). These find-
ings suggest that bevacizumab may merit 
further investigation in NSCLC patients 
with symptomatic, heavily pretreated, 
and/or radioresistant brain metastases.
In addition, a recent retrospective 
study demonstrated that brain metastases 
are considerably common at the time of 
diagnosis and also at the time of disease 
progression in epidermal growth fac-
tor receptor (EGFR)-positive or ALK-
positive NSCLC treated with tyrosine 
kinase inhibitors (TKIs).5 Considering 
that bevacizumab may have some booster 
effect for brain metastases and that brain 
metastases have a negative impact on sur-
vival in EGFR-positive NSCLC treated 
with EGFR-TKI as well,6 prospective 
evaluation of bevacizumab in combi-
nation with TKI in EGFR-positive or 
ALK-positive NSCLC patients with brain 
metastases would be particularly valuable.
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FIGURE 1.  Magnetic resonance 
imaging of the brain (A,B) before and 
(C,D) after whole brain irradiation, 
(E,F) after two cycles of chemotherapy 
of bevacizumab, paclitaxel, and 
carboplatin.
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To the Editor:
Su and Rau1 have recently reported 
a case of non–small-cell lung cancer 
(NSCLC) of great interest. The patient, 
with anaplastic lymphoma kinase (ALK)-
positive adenocarcinoma of the lung with 
brain metastases, was initially treated with 
whole-brain irradiation and then treated 
with chemotherapy consisting of peme-
trexed and cisplatin; however, her brain 
metastases increased in size accompanied 
by muscle weakness and myoclonic jerks 
after two cycles of chemotherapy. The 
